Cancer development has been ascribed with diverse genetic variations which are identified in both mitochondrial and nuclear genomes. Mitochondrial DNA (mtDNA) alterations have been detected in several tumours which include lung, colorectal, renal, pancreatic and breast cancer. Several studies have explored the breast tumour-specific mtDNA alteration mainly in Western population. This study aims to identify mtDNA alterations of 20 breast cancer patients in Malaysia by next generation sequencing analysis. Twenty matched tumours with corresponding normal breast tissues were obtained from female breast cancer patients who underwent mastectomy. Total DNA was extracted from all samples and the entire mtDNA (16.6kb) was amplified using long range PCR amplification. The amplified PCR products were sequenced using mtDNA next-generation sequencing (NGS) on an Illumina Miseq platform. Sequencing involves the entire mtDNA (16.6kb) from all pairs of samples with high-coverage (~ 9,544 reads per base). MtDNA variants were called and annotated using mtDNA-Server, a web server. A total of 18 of 20 patients had at least one somatic mtDNA mutation in their tumour samples. Overall, 65 somatic mutations were identified, with 30 novel mutations. The majority (59%) of the somatic mutations were in the coding region, whereas only 11% of the mutations occurred in the D-loop. Notably, somatic mutations in protein-coding regions were non-synonymous (49%) in which 15.4% of them are potentially deleterious. A total of 753 germline mutations were identified and four of which were novel mutations. Compared to somatic alterations, less than 1% of germline missense mutations are harmful. The findings of this study may enhance the current knowledge of mtDNA alterations in breast cancer. To date, the catalogue of mutations identified in this study is the first evidence of mtDNA alterations in Malaysian female breast cancer patients.

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
2. Azizah, A. M., Nor Saleha, I. T., Noor Hashimah, A., Asmah, Z. A., & Mastulu, W. (2016). Malaysian national cancer registry report 2007–2011: Malaysia cancer statistics, data and figure. National Cancer Institute, Ministry of Health Malaysia.
3. Yip, C. H., Bhoo-Pathy, N., & Teo, S. H. (2014). A review of breast cancer research in Malaysia. Medical Journal of Malaysia, 69(Suppl A), 8–22.
4. Ministry of Health Malaysia & Academy of Medicine of Malaysia. (2010). Clinical practice guidelines for the management of breast cancer (2nd ed.). http://www.acadmed.org.my
5. Chinnery, P. F., & Hudson, G. (2013). Mitochondrial genetics. British Medical Bulletin, 106(1), 135–159.
6. Vakifahmetoglu-Norberg, H., Ouchida, A. T., & Norberg, E. (2017). The role of mitochondria in metabolism and cell death. Biochemical and Biophysical Research Communications, 482(3), 426–431. https://doi.org/10.1016/j.bbrc.2016.11.012
7. Porporato, P. E., Filigheddu, N., Bravo-San Pedro, J. M., Kroemer, G., & Galluzzi, L. (2018). Mitochondrial metabolism and cancer. Cell Research, 28(3), 265–280. https://doi.org/10.1038/cr.2017.155
8. Hagström, E., Freyer, C., Battersby, B. J., Stewart, J. B., & Larsson, N. G. (2013). No recombination of mtDNA after heteroplasmy for 50 generations in the mouse maternal germline. Nucleic Acids Research, 42(2), 1111–1116. https://doi.org/10.1093/nar/gkt932
9. Wallace, D. C., & Chalkia, D. (2013). Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease. Cold Spring Harbor Perspectives in Biology, 5(11), a021220. https://doi.org/10.1101/cshperspect.a021220
10. Penta, J. S., Johnson, F. M., Wachsman, J. T., & Copeland, W. C. (2001). Mitochondrial DNA in human malignancy. Mutation Research, 488(2), 119–133.
11. Lagouge, M., & Larsson, N. G. (2013). The role of mitochondrial DNA mutations and free radicals in disease and ageing. Journal of Internal Medicine, 273(6), 529–543. https://doi.org/10.1111/joim.12002
12. Scheibye-Knudsen, M., Fang, E. F., Croteau, D. L., Wilson III, D. M., & Bohr, V. A. (2015). Protecting the mitochondrial powerhouse. Trends in Cell Biology, 25(3), 158–170. https://doi.org/10.1016/j.tcb.2014.12.002
13. Schon, E. A., DiMauro, S., & Hirano, M. (2012). Human mitochondrial DNA: Roles of inherited and somatic mutations. Nature Reviews Genetics, 13(12), 878–890. https://doi.org/10.1038/nrg3275
14. Duchen, M. R., & Szabadkai, G. (2010). Roles of mitochondria in human disease. Essays in Biochemistry, 47, 115–137. https://doi.org/10.1042/bse0470115
15. Yadav, N., & Chandra, D. (2013). Mitochondrial DNA mutations and breast tumorigenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1836(2), 336–344.
16. Li, L., Chen, L., Li, J., Zhang, W., Liao, Y., Chen, J., et al. (2016). Correlational study on mitochondrial DNA mutations as potential risk factors in breast cancer. Oncotarget, 7(21), 31270. https://doi.org/10.18632/oncotarget.8456
17. Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A., & Higgins, G. S. (2018). Oxidative phosphorylation as an emerging target in cancer therapy. Clinical Cancer Research, 24(11), 2482–2490. https://doi.org/10.1158/1078-0432.CCR-17-3612
18. He, X., Zhou, A., Lu, H., Chen, Y., Huang, G., Yue, X., et al. (2013). Suppression of mitochondrial complex I influences cell metastatic properties. PLOS ONE, 8(4), e61677. https://doi.org/10.1371/journal.pone.0061677
19. Owens, K. M., Kulawiec, M., Desouki, M. M., Vanniarajan, A., & Singh, K. K. (2011). Impaired OXPHOS complex III in breast cancer. PLOS ONE, 6(8), e23846. https://doi.org/10.1371/journal.pone.0023846
20. Baharudin, N. T., Jaafar, H., & Zainuddin, Z. (2012). Association of mitochondrial DNA 10398 polymorphism in invasive breast cancer in Malay population of Peninsular Malaysia. Malaysian Journal of Medical Sciences, 19(1), 36–43.
21. Qiagen. (2016). QIAamp DNA Mini Blood Mini Handbook. https://www.qiagen.com
22. Stawski, H. (2013). Preparing whole genome human mitochondrial DNA libraries for next generation sequencing using Illumina Nextera XT. Western Carolina University.
23. Illumina, Inc. (2016). Human mtDNA Genome guide. https://support.illumina.com
24. Illumina, Inc. (2016). MiSeq system denature and dilute libraries guide. https://support.illumina.com
25. Kircher, M., Stenzel, U., & Kelso, J. (2009). Improved base calling for the Illumina Genome Analyzer using machine learning strategies. Genome Biology, 10, R83. https://doi.org/10.1186/gb-2009-10-8-r83
26. Weissensteiner, H., Forer, L., Fuchsberger, C., Schöpf, B., Kloss-Brandstätter, A., Specht, G., et al. (2016). mtDNA-Server: Next-generation sequencing data analysis of human mitochondrial DNA in the cloud. Nucleic Acids Research, 44(W1), W64–W69. https://doi.org/10.1093/nar/gkw247
27. Tan, D. J., Bai, R. K., & Wong, L. J. (2002). Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Research, 62(4), 972–976.
28. Zhu, W., Qin, W., Bradley, P., Wessel, A., Puckett, C. L., & Sauter, E. R. (2005). Mitochondrial DNA mutations in breast cancer tissue and matched nipple aspirate fluid. Carcinogenesis, 26(1), 145–152. https://doi.org/10.1093/carcin/bgh289
29. Lott, M. T., Leipzig, J. N., Derbeneva, O., Xie, H. M., Chalkia, D., Sarmady, M., et al. (2013). mtDNA variation and analysis using MITOMAP and MITOMASTER. Current Protocols in Bioinformatics, 44(1), 1–23.
30. Castellana, S., Rónai, J., & Mazza, T. (2015). MitImpact: Pre-computed pathogenicity predictions of human mitochondrial variants. Human Mutation, 36(2), E2413–E2422. https://doi.org/10.1002/humu.22826
31. Li, B., Krishnan, V. G., Mort, M. E., Xin, F., Kamati, K. K., Cooper, D. N., et al. (2009). Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics, 25(21), 2744–2750.
32. McMahon, S., & LaFramboise, T. (2014). Mutational patterns in the breast cancer mitochondrial genome. Carcinogenesis, 35(5), 1046–1054. https://doi.org/10.1093/carcin/bgu040
33. Sonney, S., Leipzig, J., Lott, M. T., Zhang, S., Procaccio, V., Wallace, D. C., et al. (2017). Predicting pathogenicity of mitochondrial tRNA variants with MitoTIP. PLOS Computational Biology, 13(12), e1005867. https://doi.org/10.1371/journal.pcbi.1005867
34. Kirches, E. (2017). mtDNA as a cancer marker: A finally closed chapter? Current Genomics, 18(3), 255–267.
35. De Paepe, B. (2012). Mitochondrial markers for cancer: relevance to diagnosis and prognosis. ISRN Pathology, 2012, 1–9.
36. Jiménez-Morales, S., Pérez-Amado, C. J., Langley, E., & Hidalgo-Miranda, A. (2018). Overview of mitochondrial germline variants in breast cancer. International Journal of Oncology, 53(3), 923–936. https://doi.org/10.3892/ijo.2018.4472
37. Hertweck, K. L., & Dasgupta, S. (2017). The landscape of mtDNA modifications in cancer. Frontiers in Oncology, 7, 262. https://doi.org/10.3389/fonc.2017.00262
38. Stoneking, M. (2000). Hypervariable sites in mtDNA control region are mutational hotspots. American Journal of Human Genetics, 67(4), 1029–1032.
39. Vartak, R., Deng, J., & Fang, H. (2015). Redefining roles of mitochondrial DNA-encoded subunits in respiratory Complex I assembly. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1852(7), 1531–1539.